TY - JOUR
T1 - Obesity Paradox in Atrial Fibrillation
T2 - Implications for Outcomes and Relationship with Oral Anticoagulant Drugs
AU - Proietti, Marco
AU - Boriani, Giuseppe
PY - 2020
Y1 - 2020
N2 - In the last 40 years, concern about the obesity epidemic has increased. Data from the current literature highlight a strong relationship between obesity and atrial fibrillation (AF), particularly in relation to an increased risk for incident and recurrent AF. A phenomenon called the “obesity paradox” has emerged: the apparently counterintuitive evidence from epidemiological data indicating that overweight and obese patients may have a better prognosis than healthy-weight patients. A differential impact of oral anticoagulants (OACs) in terms of effectiveness and safety in the various body mass index categories has been postulated, particularly in the comparison between non-vitamin-K antagonist oral anticoagulants and vitamin K antagonists. This review aims to summarize the evidence on the impact of obesity in patients with AF, focusing on descriptions of the obesity paradox and its relationships with OAC treatment.
AB - In the last 40 years, concern about the obesity epidemic has increased. Data from the current literature highlight a strong relationship between obesity and atrial fibrillation (AF), particularly in relation to an increased risk for incident and recurrent AF. A phenomenon called the “obesity paradox” has emerged: the apparently counterintuitive evidence from epidemiological data indicating that overweight and obese patients may have a better prognosis than healthy-weight patients. A differential impact of oral anticoagulants (OACs) in terms of effectiveness and safety in the various body mass index categories has been postulated, particularly in the comparison between non-vitamin-K antagonist oral anticoagulants and vitamin K antagonists. This review aims to summarize the evidence on the impact of obesity in patients with AF, focusing on descriptions of the obesity paradox and its relationships with OAC treatment.
UR - http://www.scopus.com/inward/record.url?scp=85074478826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074478826&partnerID=8YFLogxK
U2 - 10.1007/s40256-019-00374-0
DO - 10.1007/s40256-019-00374-0
M3 - Review article
C2 - 31583532
AN - SCOPUS:85074478826
VL - 20
SP - 125
EP - 137
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
SN - 1175-3277
IS - 2
ER -